NCT03298464View on ClinicalTrials.gov

Study of NGM313 in Obese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 11, 2017

Primary Completion Date

June 19, 2018

Study Completion Date

July 17, 2018

Conditions
Obese
Interventions
BIOLOGICAL

NGM313

Subcutaneous injection

DRUG

Pioglitazone

White to off-white round tablet

Trial Locations (1)

91911

Prosciento, Chula Vista

Sponsors
All Listed Sponsors
lead

NGM Biopharmaceuticals, Inc

INDUSTRY